Phase 1/2 trial of MKC-1 and pemetrexed in patients (pts) with advanced NSCLC

19052 Background: MKC-1 is a novel oral cell cycle inhibitor with in vitro and in vivo activity against many tumor cell lines, including NSCLC and multi-drug resistant cell lines and single agent a...